Subsequent in vivo studies in a lung cancer xenograft model expressing the tumor antigen EphA2 revealed that EphA2-TEA-VV, when applied in combination with adoptively transferred human T cells, mediated superior antitumor activity when compared with control VV plus T cells. Here, EPHA2 is linked to lung carcinoma.